Valuation: Tsubota Laboratory Incorporated

Market Cap 668.07Cr 4.2Cr 3.7Cr 3.48Cr 3.18Cr 5.95Cr 403.39Cr 5.99Cr 42Cr 16Cr 205.3Cr 16Cr 15Cr P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 577.97Cr 3.64Cr 3.2Cr 3.01Cr 2.75Cr 5.14Cr 348.98Cr 5.18Cr 36Cr 14Cr 177.61Cr 14Cr 13Cr EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
12/08 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
17/06 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
01/06 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
15/05 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
15/05 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
13/02 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
13/02 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
12/25/12 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
17/25/17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
20/24/20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
19/22/19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
20/22/20 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
Manager TitleAgeSince
President 71 01/02/2019
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/02/2019
Director/Board Member 70 01/06/2020
Director/Board Member 55 01/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.2Cr
+1.46%+4.59%+8.65%+33.71% 4.8TCr
+2.67%+2.07%+51.74%+38.37% 4.53TCr
-1.38%+1.84%+9.13%+88.88% 4.09TCr
+4.78%+1.48%+359.03%+566.20% 4.28TCr
-0.62%-1.61%+5.30%+46.02% 2.96TCr
+0.56%+0.88%+24.79%+155.71% 1.73TCr
+2.05%+1.09%+25.56%+41.67% 1.53TCr
+3.39%-3.49% - - 1.52TCr
+7.38%+2.34%+3.80% - 1.48TCr
Average +2.03%+1.02%+61.00%+138.65% 2.99TCr
Weighted average by Cap. +1.94%+1.56%+76.91%+150.21%

Financials

2025 2026
Net sales 135.7Cr 85.36L 75.08L 70.78L 64.57L 1.21Cr 82Cr 1.22Cr 8.49Cr 3.29Cr 42Cr 3.2Cr 3.14Cr 20Cr 12.58L 11.07L 10.43L 10L 17.8L 12Cr 17.94L 1.25Cr 48.51L 6.15Cr 47.23L 46.21L
Net income 20Cr 12.89L 11.34L 10.69L 10L 18.24L 12Cr 18.39L 1.28Cr 49.72L 6.3Cr 48.41L 47.36L -76Cr -47.87L -42.1L -39.69L -36.21L -67.72L -46Cr -68.25L -4.76Cr -1.85Cr -23Cr -1.8Cr -1.76Cr
Net Debt -144.8Cr -91.08L -80.12L -75.52L -68.9L -1.29Cr -87Cr -1.3Cr -9.06Cr -3.51Cr -44Cr -3.42Cr -3.35Cr -90Cr -56.67L -49.85L -46.99L -42.88L -80.18L -54Cr -80.81L -5.64Cr -2.19Cr -28Cr -2.13Cr -2.08Cr
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-